Skip to main content

Table 2 Dosage changes in phosphate binders and cinacalcet

From: Long-term observational study in Japanese hemodialysis patients who completed a 3-year clinical study of lanthanum carbonate

  Phase III study (1-year study and additional 2-year study) 5-year follow-up observational study
Dosage (mg/day) Start (2005) 1 year after (2006) 2 years after (2007) 3 years after (2008) 4 years after (2009) 5 years after (2010) 6 years after (2011) 7 years after (2012) 8 years after (2013)
Lanthanum carbonate 1700.0 ± 879.4 (750–3000) (n = 30) 1625.0 ± 966.6 (750–3750) (n = 30) 1525.0 ± 775.0 (750–3750) (n = 30) 1550.0 ± 834.1 (750–3750) (n = 30) 1500 (n = 1) 863.6 ± 452.3 (250–1500) (n = 11) 1113.6 ± 563.1 (500–2250) (n = 11) 970.6 ± 413.5 (250–1500) (n = 17) 1125.0 ± 413.5 (500–1500) (n = 18)
Calcium carbonate 2035.7 ± 929.7 (250–3000) (n = 21) 2133.3 ± 766.9 (1000–3000) (n = 15) 2125.0 ± 974.7 (1000–4500) (n = 16) 2318.2 ± 783.3 (1500–3000) (n = 11) 1792.3 ± 950.0 (300–3000) (n = 13)
Sevelamer hydrochloride 1968.8 ± 1263.8 (750–4500) (n = 8) 2035.7 ± 940.2 (750–3750) (n = 7) 1875.0 ± 1131.9 (750–3750) (n = 10) 1607.1 ± 1097.9 (750–3750) (n = 7) 1821.4 ± 954.3 (750–3750) (n = 7)
Cinacalcet hydrochloride 40.0 ± 12.9 (25–50) (n = 10) 44.2 ± 18.1 (25–75) (n = 13) 41.4 ± 21.8 (25–100) (n = 16) 42.5 ± 19.9 (25–75) (n = 15) 39.8 ± 17.8 (25–75) (n = 16)
  1. Data are given as mean ± standard deviation, range and number